Sign in or create an account to add this stock to your watchlist.
About Gilead Sciences (NASDAQ:GILD)
Warning: file_get_contents(): SSL: Handshake timed out in /home/ledgergazette/public_html/download.php on line 7
Warning: file_get_contents(): Failed to enable crypto in /home/ledgergazette/public_html/download.php on line 7
Warning: file_get_contents(https://ca.finance.yahoo.com/quote/GILD/profile?p=GILD): failed to open stream: operation failed in /home/ledgergazette/public_html/download.php on line 7
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GILD
CUSIP37555810
Phone650-574-3000
Debt
Debt-to-Equity Ratio1.32
Current Ratio2.84
Quick Ratio2.75
Price-To-Earnings
Trailing P/E Ratio8.20
Forward P/E Ratio12.21
P/E Growth-6.11
Sales & Book Value
Annual Sales$26.11 billion
Price / Sales3.50
Cash Flow$9.6205 per share
Price / Cash7.30
Book Value$15.69 per share
Price / Book4.48
Profitability
EPS (Most Recent Fiscal Year)$8.56
Net Income$4.63 billion
Net Margins14.03%
Return on Equity45.49%
Return on Assets15.63%
Miscellaneous
Employees10,000
Outstanding Shares1,300,260,000
Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions
What is Gilead Sciences' stock symbol?
Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."
How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?
Gilead Sciences declared a quarterly dividend on Tuesday, May 1st. Stockholders of record on Friday, June 15th will be paid a dividend of $0.57 per share on Thursday, June 28th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.25%. The ex-dividend date is Thursday, June 14th. View Gilead Sciences' Dividend History.
How were Gilead Sciences' earnings last quarter?
Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings data on Tuesday, May, 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.67 by $0.19. The biopharmaceutical company had revenue of $5.09 billion for the quarter, compared to analysts' expectations of $5.40 billion. Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The business's quarterly revenue was down 21.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.23 EPS. View Gilead Sciences' Earnings History.
When is Gilead Sciences' next earnings date?
What price target have analysts set for GILD?
24 brokers have issued 1 year target prices for Gilead Sciences' shares. Their predictions range from $72.00 to $105.00. On average, they anticipate Gilead Sciences' share price to reach $87.9885 in the next twelve months. View Analyst Ratings for Gilead Sciences.
What are Wall Street analysts saying about Gilead Sciences stock?
Here are some recent quotes from research analysts about Gilead Sciences stock:
- 1. According to Zacks Investment Research, "Gilead’s first-quarter results were disappointing with both earnings and sales missing estimates as the magnitude of the decline in HCV sales was wider-than-expected due to lower patient starts and increasing competition. Nevertheless, Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy to drive growth. The HIV franchise maintains momentum driven by the rapid adoption of Descovy-based regimens. The FDA approval of Biktarvy has further widened the portfolio. The CHMP has also adopted a positive opinion on the regimen and a tentative approval is expected in the third-quarter. The initial uptake of Yescarta is encouraging. Meanwhile, Gilead is intending to foray into the NASH market with selonsertib and filgotinib. Both the candidates are being evaluated in late stage studies and a tentative approval will diversify Gilead’s portfolio.Shares have performed better than the industry in the last twelve months." (5/7/2018)
- 2. Needham & Company LLC analysts commented, "Gilead reported $5.09B 1Q18 total revenue, below our $5.52B and consensus $5.3B ests. Product sales were $5.00B, below our $5.41B est. Gilead continues to lose share to Abbvie in HCV. Trend is worrisome, although mgmt still guiding for market share stabilization mid-2018. HIV sales in 1Q18 also disappointed, reportedly driven by bigger than expected seasonal inventory draw-down and generic TDF. Growth in HIV (i.e. Biktarvy success) is critical. NASH program has not yet distinguished itself, awaiting data from selonsertib Phase 3 trials (1H19) and 48wk combination Phase 2 trials (2020). Yescarta and cell therapy programs are in early stages." (5/2/2018)
- 3. Leerink Swann analysts commented, "RARE’s 4Q report this afternoon was relatively in line with expectations. Incremental clinical updates for burosumab in young children and in adults with osteomalacia (bone softening) in the report further support the drug’s utility in both populations. The year ahead is shaping up to be catalyst-rich for RARE, with data from two gene therapy programs, the Phase 3 of trihep in Glut1 DS, and a decision on trihep registration plans in FAOD expected over the coming months. Although we continue to expect a slow rollout of burosumab (PDUFA date 4/17/18) and Mepsevii, we see opportunity for further upside in shares over the course of 2018. Maintain OW." (2/22/2018)
- 4. BMO Capital Markets analysts commented, "Early biopotency signals from a single patient dosed with ABO-101 (for Sanfilippo B), demonstrate targeted reduction on toxic sugars." (2/7/2018)
- 5. Maxim Group analysts commented, "We returned from Beijing, China and listened as Tim Moore, EVP of Technical Operations and the CEO of Fosun Kite Biotechnology co. (Richard Wang) presented manufacturing plans for the launch of Yescarta, and the opportunity in China (see the slides in the pages that follow). Suffice to say, we were impressed and left clear with the notion that Gilead (and Kite) can overcome manufacturing challenges to commercialize in the U.S. and globally, especially China, this new innovative therapy. As a result, we are upgrading Gilead to Buy, from Hold and establishing a $94 price target." (11/30/2017)
Are investors shorting Gilead Sciences?
Gilead Sciences saw a increase in short interest in May. As of May 31st, there was short interest totalling 18,137,359 shares, an increase of 11.4% from the May 15th total of 16,281,660 shares. Based on an average trading volume of 6,570,454 shares, the short-interest ratio is currently 2.8 days. Currently, 1.4% of the shares of the company are sold short.
Who are some of Gilead Sciences' key competitors?
Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), argenx (ARGX), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), China Biologic Products (CBPO) and Aerie Pharmaceuticals (AERI).
Who are Gilead Sciences' key executives?
Gilead Sciences' management team includes the folowing people:
- Dr. John F. Milligan, CEO, Pres & Director (Age 57)
- Ms. Robin L. Washington, CFO & Exec. VP (Age 55)
- Dr. Norbert W. Bischofberger, Exec. VP of R&D and Chief Scientific Officer (Age 62)
- Mr. Gregg H. Alton, Exec. VP of Corp. & Medical Affairs and Interim Head of International Commercial Operations (Age 52)
- Mr. Kevin B. Young, Advisory (Age 60)
Has Gilead Sciences been receiving favorable news coverage?
Media stories about GILD stock have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Gilead Sciences earned a media sentiment score of 0.22 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.21 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Gilead Sciences' major shareholders?
Gilead Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.07%), Northern Trust Corp (1.27%), Franklin Resources Inc. (1.03%), Amundi Pioneer Asset Management Inc. (0.65%), Boston Partners (0.62%) and OppenheimerFunds Inc. (0.54%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.
Which major investors are selling Gilead Sciences stock?
GILD stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., CI Investments Inc., Swiss National Bank, Amundi Pioneer Asset Management Inc., Envestnet Asset Management Inc., Sentry Investments Corp., Franklin Resources Inc. and Legal & General Group Plc. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.
Which major investors are buying Gilead Sciences stock?
GILD stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Farallon Capital Management LLC, State Treasurer State of Michigan, BlackRock Inc., PointState Capital LP, Diamond Hill Capital Management Inc., Millennium Management LLC and Mackay Shields LLC. View Insider Buying and Selling for Gilead Sciences.
How do I buy shares of Gilead Sciences?
Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gilead Sciences' stock price today?
One share of GILD stock can currently be purchased for approximately $70.23.
How big of a company is Gilead Sciences?
Gilead Sciences has a market capitalization of $91.32 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.
How can I contact Gilead Sciences?
Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]
MarketBeat Community Rating for Gilead Sciences (GILD)
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Gilead Sciences (NASDAQ:GILD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
24 Wall Street analysts have issued ratings and price targets for Gilead Sciences in the last 12 months. Their average twelve-month price target is $87.9885, suggesting that the stock has a possible upside of 25.29%. The high price target for GILD is $105.00 and the low price target for GILD is $72.00. There are currently 9 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.63 | 2.61 | 2.65 | 2.61 |
| Ratings Breakdown: | 0 Sell Rating(s)
9 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
9 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
9 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
11 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $87.9885 | $88.1458 | $88.7033 | $84.8654 |
| Price Target Upside: | 25.29% upside | 31.07% upside | 12.07% upside | 14.34% upside |
Gilead Sciences (NASDAQ:GILD) Consensus Price Target History
Gilead Sciences (NASDAQ:GILD) Analyst Ratings History
Show:
(Data available from 6/17/2016 forward)
Gilead Sciences (NASDAQ:GILD) Dividend Information
Gilead Sciences pays an annual dividend of $2.28 per share, with a dividend yield of 3.25%. GILD's next quarterly dividend payment will be made on Thursday, June 28. Gilead Sciences pays out 26.64% of its earnings out as a dividend.
| Next Dividend: | 6/28/2018 |
| Annual Dividend: | $2.28 |
| Dividend Yield: | 3.25% |
| Payout Ratio(s): | 26.64% (Trailing 12 Months of Earnings)
39.65% (Based on This Year's Estimates)
36.66% (Based on Next Year's Estimates)
23.70% (Based on Cash Flow)
|
Gilead Sciences (NASDAQ:GILD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/1/2018 | quarterly | $0.57 | 3.14% | 6/14/2018 | 6/15/2018 | 6/28/2018 |
| 2/6/2018 | quarterly | $0.57 | 3.02% | 3/15/2018 | 3/16/2018 | 3/29/2018 |
| 10/26/2017 | quarterly | $0.52 | 2.7% | 12/14/2017 | 12/15/2017 | 12/28/2017 |
| 7/26/2017 | quarterly | $0.52 | 2.78% | 9/14/2017 | 9/15/2017 | 9/28/2017 |
| 5/2/2017 | quarterly | $0.52 | 3.09% | 6/14/2017 | 6/16/2017 | 6/29/2017 |
| 2/7/2017 | quarterly | $0.52 | 3.11% | 3/14/2017 | 3/16/2017 | 3/30/2017 |
| 11/1/2016 | quarterly | $0.47 | 2.59% | 12/13/2016 | 12/15/2016 | 12/29/2016 |
| 7/25/2016 | quarterly | $0.47 | 2.32% | 9/14/2016 | 9/16/2016 | 9/29/2016 |
| 4/28/2016 | quarterly | $0.47 | 2.13% | 6/14/2016 | 6/16/2016 | 6/29/2016 |
| 2/2/2016 | quarterly | $0.43 | 1.99% | 3/14/2016 | 3/16/2016 | 3/30/2016 |
| 10/27/2015 | quarterly | $0.43 | 1.59% | 12/14/2015 | 12/16/2015 | 12/30/2015 |
| 7/28/2015 | quarterly | $0.43 | 1.49% | 9/14/2015 | 9/16/2015 | 9/29/2015 |
| 4/30/2015 | quarterly | $0.43 | | 6/12/2015 | 6/16/2015 | 6/29/2015 |
(Data available from 1/1/2013 forward)
Gilead Sciences (NASDAQ GILD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 77.71%
Gilead Sciences (NASDAQ GILD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/1/2018 | John C Martin | Director | Sell | 50,000 | $68.13 | $3,406,500.00 | 3,067,762 |  |
| 5/4/2018 | John Francis Cogan | Director | Sell | 5,836 | $65.09 | $379,865.24 | 58,455 | |
| 5/1/2018 | John C Martin | Director | Sell | 50,000 | $72.19 | $3,609,500.00 | 3,067,762 | |
| 4/27/2018 | John Francis Cogan | Director | Sell | 5,833 | $73.91 | $431,117.03 | 58,452 | |
| 4/20/2018 | John Francis Cogan | Director | Sell | 5,833 | $73.74 | $430,125.42 | 58,452 | |
| 4/13/2018 | John Francis Cogan | Director | Sell | 5,833 | $75.56 | $440,741.48 | 58,452 | |
| 4/6/2018 | John Francis Cogan | Director | Sell | 5,833 | $74.47 | $434,383.51 | 58,452 | |
| 4/2/2018 | John C Martin | Director | Sell | 50,000 | $73.14 | $3,657,000.00 | 3,067,762 | |
| 3/23/2018 | John Francis Cogan | Director | Sell | 5,833 | $75.02 | $437,591.66 | 58,452 | |
| 3/16/2018 | John Francis Cogan | Director | Sell | 5,833 | $80.09 | $467,164.97 | 58,452 | |
| 3/12/2018 | John Francis Cogan | Director | Sell | 5,833 | $80.93 | $472,064.69 | | |
| 3/1/2018 | Gregg H Alton | EVP | Sell | 25,000 | $78.69 | $1,967,250.00 | 69,426 | |
| 3/1/2018 | John C Martin | Chairman | Sell | 50,000 | $78.65 | $3,932,500.00 | 3,067,762 | |
| 2/28/2018 | Robin L Washington | CFO | Sell | 5,000 | $80.31 | $401,550.00 | 23,749 | |
| 2/20/2018 | Gregg H Alton | EVP | Sell | 14,435 | $81.54 | $1,177,029.90 | | |
| 2/9/2018 | Gayle E Wilson | Director | Sell | 60,000 | $77.92 | $4,675,200.00 | 182,258 | |
| 2/1/2018 | Gregg H Alton | EVP | Sell | 25,000 | $83.51 | $2,087,750.00 | 62,738 | |
| 2/1/2018 | John C Martin | Chairman | Sell | 50,000 | $83.56 | $4,178,000.00 | 3,046,766 | |
| 1/16/2018 | James R Meyers | EVP | Sell | 100,000 | $80.24 | $8,024,000.00 | 102,715 | |
| 1/11/2018 | Gregg H Alton | EVP | Sell | 30,000 | $79.00 | $2,370,000.00 | 57,114 | |
| 1/2/2018 | Gregg H Alton | EVP | Sell | 15,000 | $73.87 | $1,108,050.00 | 64,613 | |
| 1/2/2018 | John C Martin | Insider | Sell | 50,000 | $73.62 | $3,681,000.00 | 3,046,766 | |
| 12/1/2017 | Gregg H Alton | EVP | Sell | 15,000 | $74.64 | $1,119,600.00 | 70,988 | |
| 12/1/2017 | John C Martin | Insider | Sell | 73,333 | $74.98 | $5,498,508.34 | 3,070,099 | |
| 11/13/2017 | John F Milligan | Insider | Sell | 220,000 | $72.88 | $16,033,600.00 | | |
| 11/1/2017 | Gregg H Alton | EVP | Sell | 15,000 | $74.82 | $1,122,300.00 | 77,363 | |
| 11/1/2017 | John C Martin | Insider | Sell | 73,333 | $75.13 | $5,509,508.29 | 3,070,099 | |
| 10/2/2017 | Gregg H Alton | EVP | Sell | 25,000 | $82.65 | $2,066,250.00 | | |
| 10/2/2017 | John C Martin | Insider | Sell | 73,333 | $82.56 | $6,054,372.48 | | |
| 9/7/2017 | Robin L Washington | CFO | Sell | 51,820 | $85.00 | $4,404,700.00 | 43,352 | |
| 9/1/2017 | Gregg H Alton | EVP | Sell | 25,000 | $83.05 | $2,076,250.00 | 101,488 | |
| 9/1/2017 | John C Martin | Insider | Sell | 73,333 | $83.11 | $6,094,705.63 | 2,996,766 | |
| 8/31/2017 | James R Meyers | EVP | Sell | 60,000 | $83.19 | $4,991,400.00 | 62,715 | |
| 8/30/2017 | Gregg H Alton | EVP | Sell | 50,000 | $79.00 | $3,950,000.00 | 113,237 | |
| 8/1/2017 | Gregg H Alton | EVP | Sell | 15,000 | $75.88 | $1,138,200.00 | 106,113 | |
| 8/1/2017 | John C Martin | Insider | Sell | 73,333 | $75.86 | $5,563,041.38 | 3,199,969 | |
| 7/21/2017 | Gregg H Alton | EVP | Sell | 40,000 | $74.00 | $2,960,000.00 | 137,488 | |
| 7/3/2017 | Gregg H Alton | EVP | Sell | 5,000 | $71.06 | $355,300.00 | 102,988 | |
| 7/3/2017 | John C Martin | Insider | Sell | 73,333 | $71.00 | $5,206,643.00 | 3,199,969 | |
| 5/9/2017 | John Francis Cogan | Director | Sell | 9,943 | $67.25 | $668,666.75 | 47,562 | |
| 4/3/2017 | John C Martin | Insider | Sell | 73,333 | $67.18 | $4,926,510.94 | 3,199,969 | |
| 3/30/2017 | Gregg H Alton | EVP | Sell | 5,000 | $67.48 | $337,400.00 | 117,988 | |
| 1/3/2017 | John C Martin | Insider | Sell | 73,337 | $73.59 | $5,396,869.83 | 3,204,433 | |
| 11/18/2016 | John W Madigan | Director | Sell | 105,000 | $74.86 | $7,860,300.00 | 121,761 | |
| 10/3/2016 | John C Martin | Insider | Sell | 100,000 | $77.63 | $7,763,000.00 | 3,231,096 | |
| 9/22/2016 | Gregg H Alton | EVP | Sell | 5,000 | $81.84 | $409,200.00 | 132,964 | |
| 9/6/2016 | John F Milligan | Insider | Sell | 70,000 | $77.74 | $5,441,800.00 | 1,128,963 | |
| 9/1/2016 | John C Martin | Insider | Sell | 100,000 | $77.48 | $7,748,000.00 | 3,287,810 | |
| 8/24/2016 | Kevin E Lofton | Director | Sell | 3,500 | $81.97 | $286,895.00 | | |
| 8/1/2016 | John C Martin | Insider | Sell | 100,000 | $80.50 | $8,050,000.00 | 4,119,727 | |
| 8/1/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $79.81 | $159,620.00 | 64,122 | |
| 7/5/2016 | John F Milligan | CEO | Sell | 112,000 | $84.33 | $9,444,960.00 | 1,170,963 | |
| 7/1/2016 | John C Martin | Chairman | Sell | 100,000 | $84.73 | $8,473,000.00 | 4,119,727 | |
| 7/1/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $83.12 | $166,240.00 | 63,122 | |
| 6/6/2016 | John F Milligan | CEO | Sell | 112,000 | $86.94 | $9,737,280.00 | 1,170,963 | |
| 6/1/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $87.02 | $174,040.00 | 63,122 | |
| 5/2/2016 | John C Martin | Chairman | Sell | 100,000 | $87.82 | $8,782,000.00 | 4,119,727 | |
| 5/2/2016 | John F Milligan | CEO | Sell | 112,000 | $87.71 | $9,823,520.00 | 1,170,963 | |
| 5/2/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $88.72 | $177,440.00 | 62,939 | |
| 4/19/2016 | Gregg H Alton | EVP | Sell | 40,000 | $100.01 | $4,000,400.00 | 177,964 | |
| 4/4/2016 | John F Milligan | CEO | Sell | 112,000 | $94.59 | $10,594,080.00 | 1,170,963 | |
| 4/1/2016 | John C Martin | Chairman | Sell | 100,000 | $93.24 | $9,324,000.00 | 4,119,727 | |
| 4/1/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $91.34 | $182,680.00 | 63,122 | |
| 3/14/2016 | Gregg H Alton | EVP | Sell | 5,000 | $90.00 | $450,000.00 | 147,090 | |
| 2/26/2016 | Gayle E Wilson | Director | Sell | 6,650 | $90.61 | $602,556.50 | 110,523 | |
| 2/1/2016 | John C. Martin | CEO | Sell | 100,000 | $83.42 | $8,342,000.00 | 3,948,066 | |
| 2/1/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $82.32 | $164,640.00 | 48,783 | |
| 1/4/2016 | John C. Martin | CEO | Sell | 100,000 | $97.68 | $9,768,000.00 | 3,948,066 | |
| 1/4/2016 | Paul Rutherford Carter | EVP | Sell | 2,000 | $99.20 | $198,400.00 | 48,783 | |
| 12/15/2015 | Norbert W. Bischofberger | EVP | Sell | 70,000 | $102.41 | $7,168,700.00 | 127,936 | |
| 12/7/2015 | John F. Milligan | COO | Sell | 100,000 | $103.18 | $10,318,000.00 | 1,029,108 | |
| 11/24/2015 | John Francis Cogan | Director | Sell | 15,000 | $105.95 | $1,589,250.00 | 44,309 | |
| 11/2/2015 | Gregg H. Alton | EVP | Sell | 12,000 | $109.38 | $1,312,560.00 | 131,422 | |
| 11/2/2015 | John C. Martin | CEO | Sell | 150,000 | $109.42 | $16,413,000.00 | 3,948,066 | |
| 11/2/2015 | Robin L Washington | CFO | Sell | 6,250 | $109.46 | $684,125.00 | | |
| 10/27/2015 | John Francis Cogan | Director | Sell | 15,000 | $110.00 | $1,650,000.00 | 44,309 | |
| 10/26/2015 | Gregg H. Alton | EVP | Sell | 5,000 | $110.00 | $550,000.00 | 133,422 | |
| 10/26/2015 | John Francis Cogan | Director | Sell | 15,000 | $110.00 | $1,650,000.00 | 44,309 | |
| 10/15/2015 | Norbert W. Bischofberger | EVP | Sell | 70,000 | $100.05 | $7,003,500.00 | 165,168 | |
| 10/7/2015 | John F. Milligan | COO | Sell | 100,000 | $99.22 | $9,922,000.00 | 1,029,108 | |
| 10/5/2015 | Gregg H. Alton | EVP | Sell | 5,000 | $100.00 | $500,000.00 | 133,422 | |
| 10/1/2015 | John C. Martin | CEO | Sell | 150,000 | $97.48 | $14,622,000.00 | 3,948,066 | |
| 10/1/2015 | Paul Rutherford Carter | EVP | Sell | 2,000 | $98.59 | $197,180.00 | 48,783 | |
| 9/15/2015 | Gregg H. Alton | EVP | Sell | 5,000 | $110.00 | $550,000.00 | 135,422 | |
| 9/15/2015 | John Francis Cogan | Director | Sell | 15,000 | $110.00 | $1,650,000.00 | 44,309 | |
| 9/8/2015 | John F. Milligan | COO | Sell | 100,000 | $103.39 | $10,339,000.00 | 1,029,108 | |
| 9/2/2015 | Robin L Washington | CFO | Sell | 6,250 | $102.20 | $638,750.00 | | |
| 9/1/2015 | John C. Martin | CEO | Sell | 150,000 | $102.73 | $15,409,500.00 | 3,948,066 | |
| 8/28/2015 | Gayle E. Wilson | Director | Sell | 21,000 | $106.96 | $2,246,160.00 | 101,769 | |
| 8/25/2015 | John C. Martin | CEO | Sell | 133,213 | $105.17 | $14,010,011.21 | 3,948,066 | |
| 8/17/2015 | Norbert W Bischofberger | EVP | Sell | 70,000 | $116.16 | $8,131,200.00 | | |
| 7/7/2015 | John F Milligan | COO | Sell | 100,000 | $114.44 | $11,444,000.00 | | |
| 6/26/2015 | John Francis Cogan | Director | Sell | 27,000 | $120.13 | $3,243,510.00 | | |
| 6/18/2015 | Paul Rutherford Carter | EVP | Sell | 10,000 | $120.00 | $1,200,000.00 | | |
| 6/15/2015 | Norbert W Bischofberger | EVP | Sell | 70,000 | $117.67 | $8,236,900.00 | | |
| 6/8/2015 | John F Milligan | COO | Sell | 100,000 | $114.05 | $11,405,000.00 | | |
| 6/1/2015 | Gregg H Alton | EVP | Sell | 17,000 | $113.64 | $1,931,880.00 | | |
| 6/1/2015 | John C Martin | CEO | Sell | 150,000 | $113.95 | $17,092,500.00 | | |
| 4/15/2015 | Norbert W Bischofberger | EVP | Sell | 70,000 | $103.84 | $7,268,800.00 | | |
| 4/8/2015 | Paul Rutherford Carter | EVP | Sell | 1,000 | $100.00 | $100,000.00 | | |
| 4/1/2015 | Gregg H Alton | EVP | Sell | 7,000 | $96.53 | $675,710.00 | | |
| 4/1/2015 | John C Martin | CEO | Sell | 150,000 | $96.74 | $14,511,000.00 | | |
| 3/2/2015 | John C Martin | CEO | Sell | 150,000 | $103.51 | $15,526,500.00 | | |
| 3/2/2015 | Paul Rutherford Carter | EVP | Sell | 2,000 | $104.18 | $208,360.00 | | |
| 3/2/2015 | Richard James Whitley | Director | Sell | 5,000 | $103.43 | $517,150.00 | | |
| 2/6/2015 | Olsen Per Wold | Director | Buy | 10,000 | $99.92 | $999,200.00 | | |
| 2/2/2015 | Gregg H Alton | EVP | Sell | 12,000 | $105.73 | $1,268,760.00 | | |
| 2/2/2015 | John C Martin | CEO | Sell | 150,000 | $105.43 | $15,814,500.00 | | |
| 2/2/2015 | Robin L Washington | CFO | Sell | 33,192 | $105.38 | $3,497,772.96 | | |
| 1/15/2015 | Norbert W Bischofberger | EVP | Sell | 70,000 | $98.47 | $6,892,900.00 | | |
| 1/8/2015 | Gregg H Alton | EVP | Sell | 5,000 | $100.89 | $504,450.00 | | |
| 1/5/2015 | John C Martin | CEO | Sell | 150,000 | $95.12 | $14,268,000.00 | | |
| 1/2/2015 | Gregg H Alton | EVP | Sell | 7,000 | $95.17 | $666,190.00 | | |
| 1/2/2015 | Richard James Whitley | Director | Sell | 5,000 | $95.22 | $476,100.00 | | |
| 12/22/2014 | John Francis Cogan | Director | Sell | 26,000 | $95.03 | $2,470,780.00 | | |
| 12/8/2014 | John F Milligan | COO | Sell | 146,823 | $106.26 | $15,601,411.98 | | |
| 12/1/2014 | John C Martin | CEO | Sell | 140,633 | $100.72 | $14,164,555.76 | | |
| 12/1/2014 | Paul Rutherford Carter | EVP | Sell | 2,000 | $100.02 | $200,040.00 | | |
| 11/3/2014 | John C Martin | CEO | Sell | 140,625 | $110.40 | $15,525,000.00 | | |
| 11/3/2014 | Richard James Whitley | Director | Sell | 5,000 | $112.02 | $560,100.00 | | |
| 11/3/2014 | Robin L Washington | CFO | Sell | 33,192 | $110.26 | $3,659,749.92 | | |
| 10/24/2014 | Paul Rutherford Carter | EVP | Sell | 2,000 | $110.00 | $220,000.00 | | |
| 10/7/2014 | John F Milligan | COO | Sell | 146,895 | $104.60 | $15,365,217.00 | | |
| 10/1/2014 | John C Martin | CEO | Sell | 140,625 | $105.91 | $14,893,593.75 | | |
| 10/1/2014 | Paul Rutherford Carter | EVP | Sell | 2,000 | $106.39 | $212,780.00 | | |
| 10/1/2014 | Richard James Whitley | Director | Sell | 5,000 | $106.99 | $534,950.00 | | |
| 9/26/2014 | Paul Rutherford Carter | EVP | Sell | 2,000 | $107.47 | $214,940.00 | | |
| 9/22/2014 | John Francis Cogan | Director | Sell | 5,000 | $106.60 | $533,000.00 | | |
| 9/8/2014 | John F Milligan | COO | Sell | 146,895 | $105.99 | $15,569,401.05 | | |
| 9/2/2014 | Gregg H Alton | EVP | Sell | 33,000 | $108.58 | $3,583,140.00 | | |
| 9/2/2014 | John C Martin | CEO | Sell | 140,625 | $108.64 | $15,277,500.00 | | |
| 8/26/2014 | Paul Rutherford Carter | EVP | Sell | 10,000 | $106.16 | $1,061,600.00 | | |
| 8/25/2014 | Robin L Washington | CFO | Sell | 4,304 | $105.87 | $455,664.48 | | |
| 8/21/2014 | John Francis Cogan | Director | Sell | 5,000 | $101.09 | $505,450.00 | | |
| 8/14/2014 | Robin L Washington | CFO | Sell | 33,556 | $95.56 | $3,206,611.36 | | |
| 8/1/2014 | Gregg H Alton | EVP | Sell | 33,000 | $91.62 | $3,023,460.00 | | |
| 8/1/2014 | John C Martin | CEO | Sell | 140,625 | $91.53 | $12,871,406.25 | | |
| 8/1/2014 | Richard James Whitley | Director | Sell | 5,000 | $91.00 | $455,000.00 | | |
| 8/1/2014 | Robin L Washington | CFO | Sell | 30,600 | $91.48 | $2,799,288.00 | | |
| 7/28/2014 | Nicholas G Moore | Director | Sell | 45,000 | $90.56 | $4,075,200.00 | | |
| 7/21/2014 | John Francis Cogan | Director | Sell | 5,000 | $89.67 | $448,350.00 | | |
| 7/8/2014 | Paul Rutherford Carter | EVP | Sell | 16,728 | $86.45 | $1,446,135.60 | | |
| 7/1/2014 | Gregg H Alton | EVP | Sell | 33,000 | $84.12 | $2,775,960.00 | | |
| 7/1/2014 | John C Martin | CEO | Sell | 140,625 | $84.84 | $11,930,625.00 | | |
| 7/1/2014 | Richard James Whitley | Director | Sell | 5,000 | $83.65 | $418,250.00 | | |
| 6/30/2014 | Robin L Washington | CFO | Sell | 10,400 | $83.98 | $873,392.00 | | |
| 6/23/2014 | John Francis Cogan | Director | Sell | 5,000 | $81.82 | $409,100.00 | | |
| 6/16/2014 | Norbert W Bischofberger | EVP | Sell | 90,000 | $80.90 | $7,281,000.00 | | |
| 6/9/2014 | Paul Rutherford Carter | EVP | Sell | 16,728 | $79.43 | $1,328,705.04 | | |
| 6/4/2014 | Robin L Washington | CFO | Sell | 6,426 | $82.52 | $530,273.52 | | |
| 6/2/2014 | Gregg H Alton | EVP | Sell | 33,000 | $81.35 | $2,684,550.00 | | |
| 6/2/2014 | Richard James Whitley | Director | Sell | 5,000 | $80.95 | $404,750.00 | | |
| 5/14/2014 | Norbert Bischofberger | EVP | Sell | 90,000 | $80.65 | $7,258,500.00 | 119,302 | |
| 5/6/2014 | Robin Washington | CFO | Sell | 3,000 | $79.91 | $239,730.00 | 49,832 | |
| 5/1/2014 | Gregg Alton | EVP | Sell | 13,000 | $79.08 | $1,028,040.00 | 130,694 | |
| 5/1/2014 | John Martin | CEO | Sell | 140,625 | $79.02 | $11,112,187.50 | 4,429,387 | |
| 5/1/2014 | Richard James Whitley | Director | Sell | 5,000 | $78.63 | $393,150.00 | 12,778 | |
| 5/1/2014 | Robin Washington | CFO | Sell | 27,600 | $79.16 | $2,184,816.00 | 49,832 | |
| 4/14/2014 | Norbert Bischofberger | EVP | Sell | 90,000 | $67.03 | $6,032,700.00 | 119,302 | |
| 4/8/2014 | John Francis Cogan | Director | Sell | 5,000 | $70.55 | $352,750.00 | 39,542 | |
| 4/8/2014 | Paul Rutherford Carter | EVP | Sell | 16,728 | $70.53 | $1,179,825.84 | 28,562 | |
| 4/1/2014 | Gregg Alton | EVP | Sell | 13,000 | $73.20 | $951,600.00 | 132,694 | |
| 4/1/2014 | John Martin | CEO | Sell | 140,625 | $73.26 | $10,302,187.50 | 4,429,387 | |
| 3/14/2014 | John Francis Cogan | Director | Sell | 14,000 | $76.44 | $1,070,160.00 | 39,542 | |
| 3/14/2014 | Norbert Bischofberger | EVP | Sell | 90,000 | $75.89 | $6,830,100.00 | 119,302 | |
| 3/10/2014 | Paul Rutherford Carter | EVP | Sell | 16,728 | $79.32 | $1,326,864.96 | 28,562 | |
| 3/3/2014 | Gregg Alton | EVP | Sell | 33,000 | $81.84 | $2,700,720.00 | 84,484 | |
| 3/3/2014 | John Martin | CEO | Sell | 140,625 | $81.74 | $11,494,687.50 | 4,257,235 | |
| 2/26/2014 | Nicholas Moore | Director | Sell | 20,000 | $84.05 | $1,681,000.00 | | |
| 2/19/2014 | Nicholas Moore | Director | Sell | 19,068 | $83.12 | $1,584,932.16 | | |
| 1/23/2014 | Kevin Young | EVP | Sell | 100,000 | $81.44 | $8,144,000.00 | 216,418 | |
| 1/21/2014 | Gregg Alton | EVP | Sell | 120,000 | $80.00 | $9,600,000.00 | 32,938 | |
| 1/14/2014 | Norbert Bischofberger | EVP | Sell | 90,000 | $74.23 | $6,680,700.00 | | |
| 10/23/2013 | Kevin Young | EVP | Sell | 75,000 | $68.56 | $5,142,000.00 | | |
| 10/14/2013 | Norbert Bischofberger | EVP | Sell | 90,000 | $62.54 | $5,628,600.00 | 2,159,643 | |
| 9/23/2013 | Kevin Young | EVP | Sell | 100,000 | $62.88 | $6,288,000.00 | 161,840 | |
| 9/16/2013 | Norbert Bischofberger | EVP | Sell | 90,000 | $63.11 | $5,679,900.00 | 2,159,643 | |
| 9/3/2013 | Gregg Alton | EVP | Sell | 30,000 | $60.99 | $1,829,700.00 | 46,938 | |
| 9/3/2013 | John Martin | CEO | Sell | 282,242 | $60.97 | $17,208,294.74 | 4,057,121 | |
| 8/30/2013 | Nicholas Moore | Director | Sell | 151,720 | $60.42 | $9,166,922.40 | | |
| 8/14/2013 | Norbert Bischofberger | EVP | Sell | 90,000 | $58.77 | $5,289,300.00 | 2,159,643 | |
| 8/1/2013 | Gregg H Alton | EVP | Sell | 30,000 | $61.49 | $1,844,700.00 | | |
| 8/1/2013 | John C Martin | CEO | Sell | 282,242 | $61.61 | $17,388,929.62 | | |
| 7/30/2013 | John W Madigan | Director | Sell | 249,000 | $61.97 | $15,430,530.00 | | |
| 7/15/2013 | Norbert W Bischofberger | EVP | Sell | 90,000 | $57.33 | $5,159,700.00 | | |
| 7/2/2013 | John Francis Cogan | Director | Sell | 17,000 | $51.66 | $878,220.00 | | |
| 7/1/2013 | Gregg H Alton | EVP | Sell | 30,000 | $52.09 | $1,562,700.00 | | |
| 7/1/2013 | John C Martin | CEO | Sell | 282,242 | $52.00 | $14,676,584.00 | | |
| 7/1/2013 | Robin L Washington | CFO | Sell | 45,600 | $52.01 | $2,371,656.00 | | |
| 6/7/2013 | John Francis Cogan | Director | Sell | 110,000 | $52.15 | $5,736,500.00 | | |
| 6/3/2013 | Gregg H Alton | EVP | Sell | 30,000 | $52.77 | $1,583,100.00 | | |
| 6/3/2013 | John C Martin | CEO | Sell | 282,242 | $52.84 | $14,913,667.28 | | |
| 2/28/2013 | Olsen Per Wold | Director | Buy | 10,000 | $43.05 | $430,500.00 | | |
| 12/3/2012 | Gregg H Alton | EVP | Sell | 44,000 | $75.10 | $3,304,400.00 | | |
| 12/3/2012 | John C Martin | CEO | Sell | 291,000 | $75.01 | $21,827,910.00 | | |
| 11/12/2012 | Robin L Washington | CFO | Sell | 55,950 | $73.11 | $4,090,504.50 | | |
| 10/3/2012 | John F Milligan | COO | Sell | 140,000 | $69.85 | $9,779,000.00 | | |
| 10/2/2012 | Robin L Washington | CFO | Sell | 29,500 | $68.62 | $2,024,290.00 | | |
| 9/4/2012 | Gregg H Alton | EVP | Sell | 44,000 | $57.50 | $2,530,000.00 | | |
(Data available from 1/1/2013 forward)
Gilead Sciences (NASDAQ GILD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Gilead: Growth Pick For Your Portfolio
seekingalpha.com - June 15 at 3:18 PM |
 | Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
finance.yahoo.com - June 15 at 3:18 PM |
| Big Biotech Set for Earnings Blowout?
finance.yahoo.com - June 15 at 3:18 PM |
| Glaxo Pops But Analysts Say It's Unlikely To Swipe Gilead Share In HIV
finance.yahoo.com - June 14 at 3:19 PM |
| Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 39th Annual Global Healthcare Conference (Transcript)
seekingalpha.com - June 14 at 6:45 AM |
 | Gilead Sciences, Inc. (GILD) Short Interest Update
www.americanbankingnews.com - June 14 at 1:22 AM |
 | Ex-Dividend Reminder: Chesapeake Utilities, Gilead Sciences and Owens & Minor
www.nasdaq.com - June 12 at 3:16 PM |
| Gilead Sciences a Top Socially Responsible Dividend Stock With 3.2% Yield (GILD)
www.nasdaq.com - June 11 at 3:09 PM |
| Gilead Sciences’ Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia
finance.yahoo.com - June 11 at 3:09 PM |
| See what the IHS Markit Score report has to say about Gilead Sciences Inc.
finance.yahoo.com - June 9 at 5:00 AM |
 | Should You Stick With Gilead Sciences?
www.fool.com - June 7 at 7:16 PM |
 | Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and ...
www.businesswire.com - June 7 at 3:13 PM |
 | Gilead unit strikes out in bid to invalidate Juno cancer treatment patent
www.reuters.com - June 7 at 3:13 PM |
| Gilead: The Turnaround Is Happening This Year
finance.yahoo.com - June 7 at 3:12 PM |
| Gilead's Evolution In Oncology, With Comments On Valuation
seekingalpha.com - June 7 at 7:10 AM |
| Gilead Collaborates with Hookipa for HBV and HIV Therapies
finance.yahoo.com - June 7 at 7:10 AM |
| Gilead's Hot Stock May Cool Fast
finance.yahoo.com - June 7 at 7:10 AM |
| Biotech Analysis Central Pharma News: Roche Abandons Drug, Gilead's Early Stage Bet, Vaxart's Phase 2 Failure
seekingalpha.com - June 6 at 5:16 AM |
| New Ebola Outbreak May Open Door to Finding Drugs That Work
finance.yahoo.com - June 6 at 5:16 AM |
| Gilead Sciences, Inc. (GILD) Director Sells $3,406,500.00 in Stock
www.americanbankingnews.com - June 5 at 10:18 PM |
| Noteworthy Monday Option Activity: MA, GILD, WDC
www.nasdaq.com - June 5 at 5:00 AM |
| Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy
finance.yahoo.com - June 5 at 5:00 AM |
| Gilead up 1% on reported settlement with Mylan over Tybost, encouraging news on new cancer treatment
seekingalpha.com - June 4 at 3:05 PM |
| Gilead up 1% on reported settlement with Mylan over Tybost
seekingalpha.com - June 4 at 3:05 PM |
| Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors
finance.yahoo.com - June 4 at 3:05 PM |
| Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting
finance.yahoo.com - June 4 at 3:05 PM |
| Gilead Sciences Leads Its First Step Toward Pipeline Recovery With Clinical Candidate Filgotinib
seekingalpha.com - June 4 at 5:16 AM |
| Gilead Sciences, Inc. (GILD) Expected to Announce Quarterly Sales of $5.15 Billion
www.americanbankingnews.com - June 3 at 2:16 AM |
| $1.51 EPS Expected for Gilead Sciences, Inc. (GILD) This Quarter
www.americanbankingnews.com - June 1 at 9:14 PM |
 | Cramer: Gilead Is Dead Money
www.benzinga.com - June 1 at 3:13 PM |
| Has the Gilead Sciences Buy Argument Collapsed?
www.fool.com - June 1 at 1:59 PM |
 | Madrigal Threatens Intercept's Lead in Fatty Liver Disease
www.bloomberg.com - May 31 at 3:01 PM |
| (Sofosbuvir/Velpatasvir), Gilead's Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection
www.businesswire.com - May 31 at 3:01 PM |
| Gilead & Galapagos Announce Positive Data on Filgotinib
www.nasdaq.com - May 31 at 3:01 PM |
 | GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN ...
globenewswire.com - May 31 at 3:01 PM |
| Annual Global Healthcare Conference on Wednesday, June 13
www.businesswire.com - May 31 at 3:01 PM |
| Why Is Gilead Sciences (GILD) Down 7.2% Since Its Last Earnings Report?
finance.yahoo.com - May 31 at 3:01 PM |
| Peaking late: How Vertex became biotech's model citizen
finance.yahoo.com - May 31 at 3:01 PM |
| Madrigal Pharma shares skyrocket 145% on positive results for liver disease therapy
finance.yahoo.com - May 31 at 3:01 PM |
| ASCO Conference Preview: Here's What Biotech Investors Need to Watch
finance.yahoo.com - May 31 at 3:01 PM |
| Gilead Sciences, Inc. (GILD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 31 at 11:42 AM |
 | Gilead Sciences (GILD), Galapagos (GLPG) Announces Results with Filgotnib in Phase 2 Study in Psoriatic Arthritis, to Progress Into Phase 3
www.streetinsider.com - May 31 at 5:28 AM |
| Gilead and Galapagos' filgotinib successful in mid-stage psoriatic arthritis study
seekingalpha.com - May 31 at 5:28 AM |
| Gilead Sciences (GILD) Now Covered by Piper Jaffray Companies
www.americanbankingnews.com - May 30 at 6:38 PM |
| The Kite Killer - TapImmune And Marker Merger Challenges Gilead
seekingalpha.com - May 30 at 3:15 PM |
| China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead’s Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection
finance.yahoo.com - May 30 at 5:02 AM |
| Pharma Companies Race to Find Wonder Drug for Obesity-Linked Liver Disease
www.bloomberg.com - May 29 at 3:07 PM |
| 3 Top Value Stocks to Buy Now
finance.yahoo.com - May 29 at 3:07 PM |
 | Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead
www.msn.com - May 24 at 3:14 PM |
| Will “Right to Try” Bill Boost Biotech ETFs?
finance.yahoo.com - May 24 at 3:14 PM |
Gilead Sciences (NASDAQ:GILD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Gilead Sciences (NASDAQ:GILD) Income Statement, Balance Sheet and Cash Flow Statement
Gilead Sciences (NASDAQ GILD) Stock Chart for Sunday, June, 17, 2018
Loading chart…
